awmsg logo



crizotinib (Xalkori®)


Reference No. 3207

Publication date:
04/01/2017


Appraisal information

crizotinib (Xalkori®) 200 mg hard capsule
crizotinib (Xalkori®) 250 mg hard capsule


Company: Pfizer Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 22/12/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, crizotinib (Xalkori®) cannot be endorsed for use within NHS Wales for the treatment of adults with ROS1-positive advanced non-small cell lung cancer.
Statement of Advice (SOA)
Download